946 related articles for article (PubMed ID: 25941994)
1. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
2. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.
Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L
Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525
[TBL] [Abstract][Full Text] [Related]
3. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
[TBL] [Abstract][Full Text] [Related]
4. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
[TBL] [Abstract][Full Text] [Related]
5. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
6. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
[TBL] [Abstract][Full Text] [Related]
8. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
Gen Y; Muramatsu T; Inoue J; Inazawa J
Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
[TBL] [Abstract][Full Text] [Related]
9. JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states.
Handoko L; Kaczkowski B; Hon CC; Lizio M; Wakamori M; Matsuda T; Ito T; Jeyamohan P; Sato Y; Sakamoto K; Yokoyama S; Kimura H; Minoda A; Umehara T
Epigenetics; 2018; 13(4):410-431. PubMed ID: 30080437
[TBL] [Abstract][Full Text] [Related]
10. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.
Kannan A; Lin Z; Shao Q; Zhao S; Fang B; Moreno MA; Vural E; Stack BC; Suen JY; Kannan K; Gao L
Oncotarget; 2016 Feb; 7(6):6576-92. PubMed ID: 26536665
[TBL] [Abstract][Full Text] [Related]
11. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
12. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
[TBL] [Abstract][Full Text] [Related]
13. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
[TBL] [Abstract][Full Text] [Related]
15. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
[TBL] [Abstract][Full Text] [Related]
16. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
18. BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.
Roe JS; Mercan F; Rivera K; Pappin DJ; Vakoc CR
Mol Cell; 2015 Jun; 58(6):1028-39. PubMed ID: 25982114
[TBL] [Abstract][Full Text] [Related]
19. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
Gryder BE; Yohe ME; Chou HC; Zhang X; Marques J; Wachtel M; Schaefer B; Sen N; Song Y; Gualtieri A; Pomella S; Rota R; Cleveland A; Wen X; Sindiri S; Wei JS; Barr FG; Das S; Andresson T; Guha R; Lal-Nag M; Ferrer M; Shern JF; Zhao K; Thomas CJ; Khan J
Cancer Discov; 2017 Aug; 7(8):884-899. PubMed ID: 28446439
[TBL] [Abstract][Full Text] [Related]
20. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
